PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24798614-20	2014	Another 25% (5/25) of subjects failing on zidovudine had more than two TAM-1 mutations.	Zidovudine	42-52	stromal interaction molecule 1	Homo sapiens	71-76	
22889300-8	2012	Virological studies showed that the combination of R284K with TAM1 mutations confers a fitness advantage in the presence of zidovudine or tenofovir.	Zidovudine	124-134	stromal interaction molecule 1	Homo sapiens	62-66	
23061604-8	2012	In conclusion, the TAM-2 pathway was selected more frequently than the TAM-1 pathway by thymidine analog drugs in HIV-1 CRF01_AE-infected patients, while the TAM-1 pathway occurred more frequently than the TAM-2 pathway in such patients with AZT-based treatment.	Zidovudine	242-245	stromal interaction molecule 1	Homo sapiens	158-163	
23061604-7	2012	The presence of TAM and the TAM-1 pathway was significantly more frequent in the AZT- than the d4T-receiving group ((OR, 2.89; 95% CI, 1.12-7.46; P< 0.05) and (OR, 3.33; 95% CI, 1.19-9.37; P< 0.05), respectively).	Zidovudine	81-84	stromal interaction molecule 1	Homo sapiens	28-33	
21393163-8	2011	Phenotypic analysis of C-terminal mutations showed that N348I, T369V and A371V conferred reduced susceptibility to zidovudine in the context of the TAM-1 and/or TAM-2 pathway, and also conferred dual resistance to nevirapine.	Zidovudine	115-125	stromal interaction molecule 1	Homo sapiens	148-153	
19457988-2	2009	In this study, the impact of Leu-214 on replication capacity and resistance to zidovudine (ZDV) of viruses containing TAM1 or TAM2 was determined.	Zidovudine	79-89	stromal interaction molecule 1	Homo sapiens	118-122	
19457988-2	2009	In this study, the impact of Leu-214 on replication capacity and resistance to zidovudine (ZDV) of viruses containing TAM1 or TAM2 was determined.	Zidovudine	91-94	stromal interaction molecule 1	Homo sapiens	118-122